Servier’s new treatment approved for coronary artery disease

Published: 2009-08-13 06:57:00

Updated: 2009-08-13 06:57:00

Servier's pipeline drug Procoralan (ivabradine), the first pure heart rate-lowering agent, has recently received an approval from the Korea Food and Drug Administration for the treatment of chronic stable angina in patients with normal sinus rhythm who have a contraindication or intolerance to be...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK